Skip to main content
SpringerLink
Log in

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

A 16-year-old patient with steroid-dependent nephrotic syndrome with more than 35 relapses developed severe relapsing idiopathic thrombocytopenic purpura (ITP). At the age of 2 years, nephrotic syndrome was diagnosed and successfully treated with a standard prednisone regimen. Frequent relapses occurred. Treatment with oral cyclophosphamide followed by cyclosporine was successful, but several attempts to withdraw steroids failed and the patient suffered from multiple relapses. At the age of 12 years, renal biopsy revealed focal segmental glomerulosclerosis and cyclosporine toxicity. A second course of oral cyclophosphamide was unsuccessful and tacrolimus resulted in the development of diabetes mellitus, which was reversed after discontinuation of the drug. At the age of 15 years the patient, still being steroid dependent, developed ITP. Neither steroids nor intravenous immunoglobulins induced permanent remission. Only weekly immunoglobulin infusions could temporarily restore the platelet count. To treat ITP in this desperate situation we decided to deplete B-cells with the monoclonal anti-CD20 antibody rituximab. Intravenous infusions of rituximab (375 mg/m2) were given once weekly for 4 consecutive weeks without adverse events. Four weeks after the first rituximab dosage, the thrombocyte count increased to normal values. There has been no subsequent relapse of either thrombocytopenia or nephrotic syndrome (on cyclosporine, without steroids) to date. We conclude that B-cell depletion with rituximab might have altered the course of steroid-dependent nephrotic syndrome in our patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Arbeitsgemeinschaft für Pädiatrische Nephrologie/APN (1987) Cyclophosphamide treatment of steroid-dependent nephrotic syndrome: comparison of eight week with twelve week course. Arch Dis Child 62:1102–1106

    Google Scholar 

  2. Niaudet P, Habib R (1994) Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 5:1049–1056

    CAS  PubMed  Google Scholar 

  3. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE (1993) Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 8:1286–1290

    CAS  PubMed  Google Scholar 

  4. Chandra M, Susin M, Abitbol C (2000) Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 14:224–226

    Article  CAS  PubMed  Google Scholar 

  5. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D (2002) Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 17:2011–2013

    Article  CAS  PubMed  Google Scholar 

  6. Donia AF, Amer GM, Ahmed HA, Gazareen SH, Molestafa FE, Shoeib AA, Ismail AM, Khamis S, Sobin MA (2002) Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children. Pediatr Nephrol 17:355–358

    Article  PubMed  Google Scholar 

  7. Kemper MJ, Altrogge H, Ludwig K, Timmermann K, Müller-Wiefel DE (2000) Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 14:772–775

    CAS  PubMed  Google Scholar 

  8. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360:923–924

    Article  CAS  PubMed  Google Scholar 

  9. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G (2003) Rituximab in idiopathic membranous nephropathy: one-year prospective study. J Am Soc Nephrol 14:1851–1857

    CAS  PubMed  Google Scholar 

  10. Johnson P, Glennie M (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30:3–8

    CAS  Google Scholar 

  11. Johnson PWM, Glennie MJ (2001) Rituximab: mechanisms and applications. Br J Cancer 85:1609–1623

    Article  Google Scholar 

  12. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    CAS  PubMed  Google Scholar 

  13. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, Rohrlich P, Peuchmaur M, Matthieu-Boue A, Fischer A, Vilmer E (2001) Chimeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 115:112–118

    Article  CAS  PubMed  Google Scholar 

  14. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R (2003) B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538–546

    PubMed  Google Scholar 

  15. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    CAS  PubMed  Google Scholar 

  16. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after therapy with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217–2224

    CAS  PubMed  Google Scholar 

  17. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952–957

    Article  CAS  PubMed  Google Scholar 

  18. Maloney DG, Grillu-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195

    CAS  PubMed  Google Scholar 

  19. Giagounidis AAN, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C (2002) Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 69:95–100

    Article  CAS  PubMed  Google Scholar 

  20. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–3861

    Article  CAS  PubMed  Google Scholar 

  21. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, Vita S de, Regazzi M, Baccarani M, Fanin R (2002) B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 87:189–195

    CAS  PubMed  Google Scholar 

  22. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673–2677

    Article  PubMed  Google Scholar 

  23. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B (2002) Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 116:465–467

    Article  PubMed  Google Scholar 

  24. Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888

    Article  CAS  PubMed  Google Scholar 

  25. Garrett HE Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R (2002) Treatment of humoral rejection with rituximab. Ann Thorac Surg 74:1240–1242

    Article  PubMed  Google Scholar 

  26. Franke D, Zimmering M, Wolfish N, Ehrich JHH, Filler G (2000) Treatment of FSGS with plasma exchange and immunadsorption. Pediatr Nephrol 14:965–969

    CAS  PubMed  Google Scholar 

  27. Moulin B, Ronco PM, Mougenot B, Francois A, Fillastre JP, Mignon F (1992) Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 42:127–135

    CAS  PubMed  Google Scholar 

  28. Lama G, Luongo I, Tirino G, Borriello A, Carangio C, Salsano ME (2002) T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis 39:958–965

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Erlangen-Nürnberg, Loschgestrasse 15, 91054 Erlangen, Germany

    Kerstin Benz, Jörg Dötsch, Wolfgang Rascher & Daniel Stachel

Authors
  1. Kerstin Benz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Dötsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Rascher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Stachel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg Dötsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benz, K., Dötsch, J., Rascher, W. et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19, 794–797 (2004). https://doi.org/10.1007/s00467-004-1434-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-004-1434-z

Keywords

Search

Navigation